2023-03-16

Jiuzhitang Maker's clinical-grade stem cell preparation passes multiple prestigious certifications.

Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereinafter referred to as "Jiuzhitang Maker"), a national high-tech enterprise specializing in the production of clinical-grade stem cells that meet both Chinese and U.S. pharmaceutical regulatory requirements, has consistently upheld the time-honored principle of Jiuzhi堂: "A healer should exert every effort, and a pharmacist should act with integrity." As a result, quality has always been prioritized as the cornerstone of Jiuzhitang Maker's development, enabling the company to achieve a series of remarkable accomplishments.

2023-02-17

Jiuzhitang Maker Receives ISO Triple-Certification Recognition

Recently, Jiuzhitang Maker officially received the prestigious ISO 9001, ISO 14001, and ISO 45001 international certifications from a leading accreditation body. This recognition fully acknowledges Jiuzhitang Maker's years of dedication to establishing robust, professional, and standardized practices in stem-cell drug R&D quality management, environmental management, and occupational health and safety management.

2023-02-10

The "Overall Plan for the Construction of the Hengqin Guangdong-Macao In-Depth Cooperation Zone" has been released, supporting the initiation of clinical research projects involving stem cells and somatic cells.

Article 32 explicitly states: Support the development of the greater health industry in the cooperation zone, including leisure and wellness, rehabilitation medicine, health management, and high-end medical services. Additionally, the article supports research and application of cutting-edge medical technologies, encouraging qualified medical institutions within the cooperation zone to conduct clinical research projects involving stem cells and somatic cells—subject to approval and registration with relevant national authorities. Furthermore, medical institutions in the cooperation zone are encouraged to strengthen collaboration and knowledge exchange with mainland Chinese or Hong Kong/Macau healthcare providers already legally engaged in clinical research on stem cells, somatic cells, and other advanced therapies, thereby enhancing their overall clinical research capabilities and expertise.

2023-02-07

Clinical Trial Recruitment: 45 Patients With Ischemic Stroke

On January 12, 2021, China's first Phase I/IIa clinical trial (ASSIST) using imported stem cells to treat ischemic stroke—initiated by Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereinafter referred to as "Jiuzhitang Maker")—officially kicked off. To date, Phase I has progressed smoothly, and the company is now recruiting 45 voluntary participants with ischemic stroke to join the Phase IIa trial.

2023-01-17

Good news keeps pouring in as Jiuzhitang Maker continues its successful journey, earning one award after another!

As the stem-cell innovation division under Jiuzhitang Group, Jiuzhitang Maker has consistently drawn significant attention from industry insiders. After several years of growth, what does Jiuzhitang Maker look like today? Here are a few recent highlights and major developments at Jiuzhitang Maker!

2022-12-01

Jiuzhitang Maker once again listed as a Beijing-based SME specializing in science and technology.

Recently, in accordance with the provisions of the "Evaluation Measures for Technology-Based Small and Medium-Sized Enterprises" (Guo Ke Fa Zheng [2017] No. 115) and the "Guidelines for Evaluation Services of Technology-Based SMEs" (Guo Ke Huo Zi [2022] No. 67), Jiuzhitang Maker has successfully passed the certification process and has once again been officially listed among Beijing's ninth batch of technology-based SMEs for 2022.

2022-11-18

Featured on the List | Jiuzhitang Maker Receives National High-Tech Enterprise Certification Once Again

Recently, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. has once again been recognized as a National High-Tech Enterprise, earning the prestigious "National High-Tech Enterprise" certificate.

2022-09-27

Jiuzhitang showcases its stem cell innovation division at the 85th National Pharmaceutical Fair.

From September 20 to 22, the 85th National Pharmaceutical Fair (hereinafter referred to as "PharmFair") was grandly held at the National Exhibition and Convention Center (Shanghai). As a renowned "Time-Honored Chinese Brand" with a rich history spanning 372 years and listed on the "Intangible Cultural Heritage Protection Catalog," Jiuzhitang showcased its comprehensive lineup of products—including prescription drugs, OTC medications, stem-cell therapies, wellness offerings, and even its cutting-edge Internet-based hospital—at this year's PharmFair, offering a full-scale glimpse into the century-old company’s evolution and core business areas.

2022-09-05

Standing Out | Jiuzhitang Maker Named to Beijing’s “Specialized, Fine, and New” Enterprise List

Recently, Jiuzhitang Maker was selected for Beijing’s “Specialized, Fine, and New” enterprise list. This inclusion is a clear testament to the company’s robust capabilities—specifically its substantial investment in stem cell research and development, its advanced stem cell expansion technologies, its promising market potential for stem cell-based pharmaceuticals, and its strong innovation-driven strength. Earlier this week, the Beijing Municipal Bureau of Economy and Information Technology announced the fourth batch of "Specialized, Fine, and New" SMEs recognized for 2022, and Jiuzhitang Maker proudly made the cut.